Avalo Therapeutics Inc

AVTXNASDAQ · USD
6.79USD+0.09 (+1.35%)
252

Avalo Therapeutics Inc (AVTX) Covered Calls

Avalo Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 12.70%, low versus the past year. AVTX's highest covered call setup is the $10.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 35.69% out of the money with 32 days to expiration, a 36.36% return until expiration, and a 414.77% theoretical annualized return. Across the setups shown, annualized returns run from 35.45% to 414.77% at strikes between $7.50 and $22.50, with 32 to 396 days to expiration, as of Nov 16, 2026.

Read more

Running AVTX covered calls helps you generate income from Avalo Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AVTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AVTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AVTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AVTX covered call is worth writing.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis.

2026-12-183210.0035.690.050.70268.0036.36414.77-0.68+0.27970.65
2027-12-1739622.50205.290.054.901518.00205.97189.85-0.68+0.5404.85
2027-12-1739620.00171.370.054.901268.00172.05158.58-0.68+0.5504.85
2027-05-2118612.5069.610.054.90518.0070.28137.92-0.68+0.5914.85
2027-12-1739617.50137.450.053.401018.00138.13127.31-0.68+0.4673.35
2027-12-1739615.00103.530.452.90808.00109.63101.05-6.11+0.478742.45
2026-12-18327.501.760.401.2553.007.1982.03-5.43+0.547,5550.85
2027-05-2118610.0035.690.352.30298.0040.4379.35-4.75+0.4831.95
2027-12-1739612.5069.610.054.90518.0070.2864.78-0.68+0.5914.85
2027-02-19957.501.760.552.2568.009.2335.45-7.46+0.59261.70

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank12.70% Low
  • Market cap (M$)387
  • 52 weeks high-72.39%
  • 52 weeks low2.60%
  • Analyst recommendationStrong Buy
    1.31
  • Target price$32.30
    375.70% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.90
  • EPS growth next 5 years26.30%

As of Nov 18, 2026